Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.67 |
| ▸ | HTR7 | P34969 | 4/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL587708 | 0.98 | SIGMAR1 (0.65) | SIGMAR1HTR7DRD4KDM4EALDH1A1 | |
| SCHEMBL4754254 | 0.90 | HTR7 (0.71) | SIGMAR1HTR7DRD4KDM4EALDH1A1 | |
| SCHEMBL2190696 | 0.87 | ALDH1A1 (0.63) | SIGMAR1HTR7DRD4KDM4EALDH1A1 | |
| SCHEMBL8744976 | 0.87 | KDM4E (0.55) | SIGMAR1HTR7DRD4KDM4EALDH1A1 | |
| SCHEMBL29137691 | 0.87 | BCL2 (0.57) | SIGMAR1HTR7KDM4EALDH1A1LMNA | |
| SCHEMBL1138135 | 0.86 | HTR7 (0.60) | SIGMAR1HTR7DRD4KDM4EALDH1A1 | |
| SCHEMBL2194377 | 0.86 | HTR7 (0.63) | HTR7KDM4EALDH1A1LMNAADORA1 | |
| SCHEMBL2190477 | 0.85 | LMNA (0.58) | SIGMAR1HTR7KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9859525 | 0.85 | HTR7 (0.62) | HTR7KDM4EALDH1A1LMNAADORA1 | |
| SCHEMBL3988740 | 0.85 | HTR7 (0.58) | SIGMAR1HTR7KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101356162-A | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-01-28 | — | — | CN | claimed |
| EP-1963296-B1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2012-02-15 | — | — | EP | disclosed |
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | disclosed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | disclosed |
| CN-101356162-A | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-01-28 | — | — | CN | disclosed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | HRH4, HRH1, HRH2 | SIGMAR1 47/4885HTR7 152/4885DRD4 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.